Joyce O'Shaughnessy

List of Publications by Year
in descending order

160	10,044	109137	35952
papers	citations	35 h-index	97 g-index

161	161	161	10462
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1738-1748.	13.9	1,390
2	Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results. Journal of Clinical Oncology, 2002, 20, 2812-2823.	0.8	1,034
3	Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2011, 364, 205-214.	13.9	754
4	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	13.9	601
5	Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing. Science Translational Medicine, 2012, 4, 162ra154.	5.8	557
6	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2019, 380, 741-751.	13.9	542
7	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 497-509.	5.1	530
8	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5218-5224.	3.2	492
9	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2â^', Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology, 2020, 38, 3987-3998.	0.8	478
10	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2141-2148.	0.8	283
11	Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3840-3847.	0.8	253
12	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications, 2019, 10, 1373.	5.8	252
13	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2022, 386, 942-950.	13.9	220
14	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 264-272.	3.0	203
15	Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2 -amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncology, The, 2013, 14, 1121-1128.	5.1	121
16	IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer. Cancer Research, 2018, 78, 5243-5258.	0.4	119
17	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer, 2017, 70, 146-155.	1.3	108
18	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. Journal of Clinical Oncology, 2017, 35, 1008-1008.	0.8	99

#	Article	IF	Citations
19	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2â^' advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment, 2018, 168, 127-134.	1.1	90
20	Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Surgery, 2020, 155, e195410.	2.2	81
21	Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncology, The, 2019, 20, 1587-1601.	5.1	80
22	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1556-1568.	5.1	79
23	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Research, 2020, 80, 5427-5434.	0.4	77
24	Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclibâ€‰+â€‰letrozole: results from MONALEESA-2. Breast Cancer Research and Treatment, 2018, 170, 535-545.	1.1	68
25	Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Research and Treatment, 2020, 184, 53-62.	1.1	64
26	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clinical Cancer Research, 2019, 25, 2433-2441.	3.2	62
27	A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Research and Treatment, 2013, 139, 107-113.	1.1	61
28	Treatment for Anthracyclineâ€Pretreated Metastatic Breast Cancer. Oncologist, 2002, 7, 4-12.	1.9	55
29	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research, 2015, 21, 4305-4311.	3.2	51
30	Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results. Clinical Breast Cancer, 2002, 3, S17-S20.	1.1	50
31	Everolimus-based combination therapies for HR+, HER2â^' metastatic breast cancer. Cancer Treatment Reviews, 2018, 69, 204-214.	3.4	48
32	Gemcitabine and trastuzumab in metastatic breast cancer. Seminars in Oncology, 2003, 30, 22-26.	0.8	44
33	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. Npj Breast Cancer, 2018, 4, 41.	2.3	41
34	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment, 2017, 165, 329-341.	1.1	40
35	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist, 2020, 25, e214-e222.	1.9	39
36	Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.. Journal of Clinical Oncology, 2022, 40, 503-503.	0.8	38

#	Article	IF	Citations
37	nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Research and Treatment, 2013, 138, 829-837.	1.1	37
38	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-8.	2.3	36
39	Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2â€“), advanced breast cancer (ABC).. Journal of Clinical Oncology, 2017, 35, 1038-1038.	0.8	35
40	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment, 2018, 170, 547-557.	1.1	32
41	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Research and Treatment, 2022, 191, 565-576.	1.1	32
42	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. Npj Breast Cancer, 2021, 7, 80.	2.3	31
43	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research, 2015, 17, 56.	2.2	30
44	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 2015, 16, 575.	0.7	28
45	Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.. Journal of Clinical Oncology, 2021, 39, 1020-1020.	0.8	27
46	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1057-1057.	0.8	27
47	Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology, 2002, 16, 17-22.	0.4	27
48	Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Research, 2020, 22, 114.	2.2	25
49	Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).. Journal of Clinical Oncology, 2020, 38, 1014-1014.	0.8	25
50	Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2017, 35, 520-520.	0.8	24
51	Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. Cancer Research, 2021, 81, GS3-04-GS3-04.	0.4	22
52	Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 2516-2516.	0.8	22
53	Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptorâ€“Positive Metastatic Breast Cancer. Clinical Cancer Research, 2016, 22, 6002-6009.	3.2	20
54	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clinical Cancer Research, 2020, 26, 1105-1113.	3.2	19

#	Article	IF	Citations
55	Phase I Trial of a Novel Anti-HER2 Antibodyâ€“Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2022, 28, 4212-4221.	3.2	19
56	Change in Topoisomerase 1â€“Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 2018, 24, 3348-3357.	3.2	18
57	Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. European Journal of Cancer, 2021, 152, 223-232.	1.3	18
58	Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.. Journal of Clinical Oncology, 2021, 39, 1038-1038.	0.8	16
59	Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).. Journal of Clinical Oncology, 2016, 34, 1086-1086.	0.8	16
60	IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2â€“) breast cancer (BC).. Journal of Clinical Oncology, 2018, 36, TPS1117-TPS1117.	0.8	16
61	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclibversusletrozole plus palbociclib for previously untreated ER+/HER2â€“ advanced breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210839.	1.4	16
62	Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. Cancer and Metastasis Reviews, 2016, 35, 323-332.	2.7	15
63	Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. European Journal of Cancer, 2018, 90, 153-155.	1.3	15
64	Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer. JAMA Network Open, 2021, 4, e214103.	2.8	15
65	A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget, 2017, 8, 85120-85135.	0.8	15
66	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 127-139.	1.1	15
67	Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. European Journal of Cancer, 2017, 76, 205-215.	1.3	14
68	Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncology, 2019, 15, 1641-1653.	1.1	14
69	Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.. Journal of Clinical Oncology, 2017, 35, 1020-1020.	0.8	14
70	Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. Neuro-Oncology, 2020, 22, 70-83.	0.6	12
71	Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, e14565-e14565.	0.8	10
72	Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.. Journal of Clinical Oncology, 2017, 35, 1089-1089.	0.8	10

#	Article	IF	Citations
73	Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open, 2016, 1, e000072.	2.0	8
74	Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology, 2003, 17, 15-21.	0.4	8
75	Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. Cancer Medicine, 2015, 4, 1289-1293.	1.3	7
76	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer, 2021, 21, e575-e583.	1.1	7
77	Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review. Pharmacoeconomics, 2022, 40, 519-558.	1.7	7
78	Sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.. Journal of Clinical Oncology, 2022, 40, 1071-1071.	0.8	7
79	Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Scientific Reports, 2020, 10, 11203.	1.6	6
80	Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. SpringerPlus, 2016, 5, 1033.	1.2	5
81	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Research and Treatment, 2021, 188, 179-190.	1.1	5
82	Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer.. Journal of Clinical Oncology, 2012, 30, 1016-1016.	0.8	5
83	Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.. Journal of Clinical Oncology, 2019, 37, 510-510.	0.8	5
84	Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigatorâ€™s choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Cancer Research, 2022, 82, OT2-11-01-OT2-11-01.	0.4	5
85	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. Cancer Research, 2022, 82, GS1-01-GS1-01.	0.4	5
86	High Dose Chemotherapy for Breast Cancer: Taking Stock. Oncologist, 2000, 5, 14-17.	1.9	4
87	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer, 2016, 56, 85-92.	1.3	4
88	Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2021, 39, 1080-1080.	0.8	4
89	Assessment of sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2021, 39, 1077-1077.	0.8	4
90	CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.. Journal of Clinical Oncology, 2019, 37, TPS1107-TPS1107.	0.8	4

#	Article	IF	Citations
91	Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial. Cancer Research, 2022, 82, PD10-05-PD10-05.	0.4	4
92	Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS1127-TPS1127.	0.8	4
93	Costâ€"effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. Immunotherapy, 2022, 14, 1027-1041.	1.0	4
94	Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2â^'metastatic breast cancer receiving single-agent chemotherapyâ€"a comparison with MONARCH 1. Breast Cancer Research and Treatment, 2020, 184, 161-172.	1.1	3
95	Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, 1017-1017.	0.8	3
96	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. Journal of Clinical Oncology, 2016, 34, LBA509-LBA509.	0.8	3
97	Androgen receptor (AR) activation in breast cancer (BC) liver metastases.. Journal of Clinical Oncology, 2017, 35, 11619-11619.	0.8	3
98	SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS1104-TPS1104.	0.8	3
99	Developments in the systemic therapy of early-stage breast cancer. European Journal of Cancer, Supplement, 2007, 5, 3-10.	2.2	2
100	Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).. Journal of Clinical Oncology, 2021, 39, TPS1107-TPS1107.	0.8	2
101	AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS1104-TPS1104.	0.8	2
102	Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).. Journal of Clinical Oncology, 2012, 30, 1018-1018.	0.8	2
103	tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2014, 32, TPS1146-TPS1146.	0.8	2
104	Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA.27.. Journal of Clinical Oncology, 2016, 34, 521-521.	0.8	2
105	Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.. Journal of Clinical Oncology, 2020, 38, 1087-1087.	0.8	2
106	EARLY real-world treatment and dosing patterns of ribociclib for metastatic breast cancer (mBC): A retrospective observational study.. Journal of Clinical Oncology, 2020, 38, e13059-e13059.	0.8	2
107	Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence.. Journal of Clinical Oncology, 2020, 38, e12648-e12648.	0.8	2
108	Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2â^' Advanced Breast Cancer. Cancer Management and Research, 2021, Volume 13, 8179-8189.	0.9	2

#	Article	IF	Citations
109	Abstract PD8-04: Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents (trastuzumab, ADCs, TKIs, and) Tj ETQq1 1 0.784314 rgBT /Overl	0.8	2
110	Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-15-P5-16-15.	0.4	2
111	Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1126-TPS1126.	0.8	2
112	Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).. Journal of Clinical Oncology, 2022, 40, 1083-1083.	0.8	2
113	Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.. Journal of Clinical Oncology, 2022, 40, TPS1121-TPS1121.	0.8	2
114	Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptorâ€“negative (HR+/HER2â^') advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).. Journal of Clinical Oncology, 2022, 40, 1015-1015.	0.8	2
115	Fulvestrant: Clinical application of an estrogen receptor downregulator. Clinical Therapeutics, 2002, 24, A31-A40.	1.1	1
116	Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane. Cancer Research, 2021, 81, GS4-01-GS4-01.	0.4	1
117	Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.. Journal of Clinical Oncology, 2021, 39, 563-563.	0.8	1
118	Abstract CT260: The FLEX real-world data platform explores new gene expression profiles and investigator initiated protocols in early stage breast cancer. , 2021, , .		1
119	A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS1144-TPS1144.	0.8	1
120	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase 2, single-arm, multicenter study.. Journal of Clinical Oncology, 2014, 32, 139-139.	0.8	1
121	Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.. Journal of Clinical Oncology, 2012, 30, 547-547.	0.8	1
122	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.. Journal of Clinical Oncology, 2014, 32, 635-635.	0.8	1
123	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2017, 35, 1016-1016.	0.8	1
124	Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess).. Journal of Clinical Oncology, 2017, 35, 514-514.	0.8	1
125	Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).. Journal of Clinical Oncology, 2017, 35, 1040-1040.	0.8	1
126	First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.. Journal of Clinical Oncology, 2019, 37, 1078-1078.	0.8	1

#	Article	IF	Citations
127	339â€...Immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy. , 2021, 9, A365-A365.		1
128	Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.. Journal of Clinical Oncology, 2022, 40, 1055-1055.	0.8	1
129	Highlights of the 2015 San Antonio Breast Cancer Symposium. Genes and Diseases, 2016, 3, 110-113.	1.5	0
130	Abstract PS18-18: Microsatellite instability high (MSI-H) detection utilizing targeted plasma based genotyping in metastatic breast cancer. , 2021, , .		0
131	Reply to K. Hashimoto and A. Shimomura. Journal of Clinical Oncology, 2021, 39, 1507-1508.	0.8	0
132	Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC).. Journal of Clinical Oncology, 2012, 30, TPS1140-TPS1140.	0.8	0
133	Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.. Journal of Clinical Oncology, 2014, 32, 629-629.	0.8	0
134	Functional comparison between genomic subtypes and protein signal transduction networks in metastatic triple-negative breast cancer tumor and stroma to identify actionable therapeutic strategies.. Journal of Clinical Oncology, 2014, 32, e22155-e22155.	0.8	0
135	Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) patients (pts) with extreme responses (ERs) to capecitabine having tumors with genomic alterations in DNA repair and chromatin remodeling genes.. Journal of Clinical Oncology, 2014, 32, 555-555.	0.8	0
136	Scalp cooling alopecia prevention trial (SCALP).. Journal of Clinical Oncology, 2014, 32, TPS9660-TPS9660.	0.8	0
137	Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy.. Journal of Clinical Oncology, 2014, 32, 625-625.	0.8	0
138	Genomic and protein alterations in 126 triple-negative (TN) metaplastic breast cancers.. Journal of Clinical Oncology, 2014, 32, 1029-1029.	0.8	0
139	Secondary nonbreast malignancies (SNBM) after primary breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 112-112.	0.8	0
140	Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies.. Journal of Clinical Oncology, 2014, 32, 140-140.	0.8	0
141	Androgen receptor activation in HER2-negative breast cancer liver metastases.. Journal of Clinical Oncology, 2016, 34, 11527-11527.	0.8	0
142	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. Journal of Clinical Oncology, 2016, 34, LBA509-LBA509.	0.8	0
143	Phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients with GR-positive (GR+) triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, e12550-e12550.	0.8	0
144	Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry.. Journal of Clinical Oncology, 2017, 35, 239-239.	0.8	0

#	Article	IF	Citations
145	Phosphoproteomic analysis of matched primary breast cancer (BC) and lymph node (LN) metastases.. Journal of Clinical Oncology, 2017, 35, 11620-11620.	0.8	0
146	Imaging features of genomic instability in circulating tumor cells (CTCs) from metastatic triple-negative breast cancer (metTNBC) patients (pts) who received PIKTOR.. Journal of Clinical Oncology, 2019, 37, e14527-e14527.	0.8	0
147	Treatment patterns and barriers involving the use of CDK4/6 inhibitors for women with HR+, HER2- breast cancer.. Journal of Clinical Oncology, 2019, 37, 27-27.	0.8	0
148	High-risk breast cancer genes at 8q22-24 and their role in over 5,000 patients evaluated with the 70-gene risk of recurrence assay.. Journal of Clinical Oncology, 2020, 38, 3569-3569.	0.8	0
149	Treatment options for patients with HR+/HER2â˜' advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy. Breast Cancer Research and Treatment, 2020, 182, 243-244.	1.1	0
150	Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. Cancer Research, 2022, 82, OT2-11-08-OT2-11-08.	0.4	0
151	Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. Cancer Research, 2022, 82, PD2-03-PD2-03.	0.4	0
152	Abstract P2-10-08: Assessment of risk factors for HER2+ breast cancer recurrence: A literature review. Cancer Research, 2022, 82, P2-10-08-P2-10-08.	0.4	0
153	Abstract OT2-07-01: The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer. Cancer Research, 2022, 82, OT2-07-01-OT2-07-01.	0.4	0
154	Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer.. Journal of Clinical Oncology, 2022, 40, 1096-1096.	0.8	0
155	Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. Journal of Clinical Oncology, 2022, 40, TPS1112-TPS1112.	0.8	0
156	The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients.. Journal of Clinical Oncology, 2022, 40, e12513-e12513.	0.8	0
157	Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial.. Journal of Clinical Oncology, 2022, 40, 556-556.	0.8	0
158	FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data.. Journal of Clinical Oncology, 2022, 40, TPS612-TPS612.	0.8	0
159	Clinical implications for patients with discordant oncotype and MammaPrint results.. Journal of Clinical Oncology, 2022, 40, 560-560.	0.8	0
160	Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study.. Journal of Clinical Oncology, 2022, 40, 3134-3134.	0.8	0